GL Pharm Tech Corp. (KOSDAQ:204840)
South Korea · Delayed Price · Currency is KRW 1,079.00
-35.00 (-3.14%)
At close: Apr 20, 2026
GL Pharm Tech Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 35,268 | 26,048 | 26,033 | 16,729 | 12,426 |
Other Revenue | - | - | -0 | - | - |
| 35,268 | 26,048 | 26,033 | 16,729 | 12,426 | |
Revenue Growth (YoY) | 35.40% | 0.06% | 55.62% | 34.63% | 3.65% |
Cost of Revenue | 20,988 | 15,772 | 17,350 | 11,881 | 8,677 |
Gross Profit | 14,279 | 10,276 | 8,683 | 4,848 | 3,749 |
Selling, General & Admin | 11,615 | 9,332 | 8,977 | 5,700 | 3,151 |
Research & Development | 1,916 | 2,325 | 2,377 | 1,968 | 2,974 |
Amortization of Goodwill & Intangibles | 204.82 | 234.81 | 223.41 | 194.07 | 192.6 |
Other Operating Expenses | 127.89 | 70.79 | 58.33 | 50.46 | 35.99 |
Operating Expenses | 14,011 | 12,043 | 11,911 | 8,103 | 6,456 |
Operating Income | 268.48 | -1,768 | -3,228 | -3,255 | -2,707 |
Interest Expense | -589.68 | -769.42 | -782.89 | -425.42 | -866.88 |
Interest & Investment Income | 98.99 | 255.82 | 111.27 | 74.9 | 17.12 |
Earnings From Equity Investments | 279.09 | 20.13 | 498.85 | 1,011 | - |
Currency Exchange Gain (Loss) | 20 | -6.68 | -15.32 | -16.48 | -0.05 |
Other Non Operating Income (Expenses) | -9.91 | -81.5 | -28.66 | 64.78 | 17.92 |
EBT Excluding Unusual Items | 66.97 | -2,350 | -3,445 | -2,546 | -3,539 |
Gain (Loss) on Sale of Investments | - | - | -499.97 | - | - |
Gain (Loss) on Sale of Assets | 9.03 | 17.5 | 0.44 | 1,714 | -24.82 |
Asset Writedown | - | - | - | - | -278.13 |
Pretax Income | 76 | -2,332 | -3,944 | -832.44 | -3,842 |
Income Tax Expense | 63.51 | 5.43 | -195.78 | -42.28 | -107.44 |
Earnings From Continuing Operations | 12.49 | -2,337 | -3,749 | -790.17 | -3,734 |
Minority Interest in Earnings | - | - | - | - | 6.87 |
Net Income | 12.49 | -2,337 | -3,749 | -790.17 | -3,727 |
Net Income to Common | 12.49 | -2,337 | -3,749 | -790.17 | -3,727 |
Shares Outstanding (Basic) | - | 75 | 62 | 62 | 51 |
Shares Outstanding (Diluted) | - | 75 | 62 | 62 | 51 |
Shares Change (YoY) | - | 21.16% | 0.34% | 21.96% | 13.03% |
EPS (Basic) | - | -31.00 | -60.23 | -12.74 | -73.29 |
EPS (Diluted) | - | -31.00 | -60.23 | -13.00 | -73.29 |
Free Cash Flow | -4,327 | -5,039 | -4,339 | -7,707 | -3,600 |
Free Cash Flow Per Share | - | -66.83 | -69.72 | -124.25 | -70.78 |
Gross Margin | 40.49% | 39.45% | 33.35% | 28.98% | 30.17% |
Operating Margin | 0.76% | -6.79% | -12.40% | -19.46% | -21.78% |
Profit Margin | 0.03% | -8.97% | -14.40% | -4.72% | -30.00% |
Free Cash Flow Margin | -12.27% | -19.35% | -16.67% | -46.07% | -28.97% |
EBITDA | 1,270 | -57.66 | -1,090 | -1,110 | -666.91 |
EBITDA Margin | 3.60% | -0.22% | -4.19% | -6.64% | -5.37% |
D&A For EBITDA | 1,002 | 1,710 | 2,138 | 2,145 | 2,040 |
EBIT | 268.48 | -1,768 | -3,228 | -3,255 | -2,707 |
EBIT Margin | 0.76% | -6.79% | -12.40% | -19.46% | -21.78% |
Effective Tax Rate | 83.57% | - | - | - | - |
Advertising Expenses | 76.51 | 70.8 | 50.73 | 21.61 | 20.58 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.